Use of Statins and Fracture: Results of 4 Prospective Studies and Cumulative Meta-analysis of Observational Studies and Controlled Trials

Archives of Internal Medicine

Volumn 164, Issue 2, 2004, Pages 146-152

  Bauer, Douglas C ^a,b,i   Mundy, Greg R ^c   Jamal, Sophie A ^d   Black, Dennis M ^b   Cauley, Jane A ^e   Ensrud, Kristine E ^f,g   Van Der Klift, Marjolein ^h   Pols, Huibert A P ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d Women's College Ambulatory Care Centre   (Canada)

^e UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g VA MEDICAL CENTER   (United States)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; FLUINDOSTATIN; GEMFIBROZIL; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; PROBUCOL; SIMVASTATIN;

ARTICLE; BODY MASS; BONE MASS; BONE METABOLISM; BONE STRENGTH; CLINICAL TRIAL; DRUG USE; FRACTURE; HIP FRACTURE; HUMAN; HYPERLIPIDEMIA; META ANALYSIS; OSSIFICATION; PRIORITY JOURNAL; RISK REDUCTION; SPINE FRACTURE;

AGED; COHORT STUDIES; FEMALE; FRACTURES, BONE; HIP FRACTURES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 0942276470     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.164.2.146     Document Type: Article

References (25)

1. Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science. 1999;286:1946-1949.
2. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA. 2000;283:3205-3210.
3. Wang PS, Solomon DH, Mogun H, Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA. 2000;283:3211-3216.
4. Chan KA, Andrade SE, Boles M, et al. Inhibitors of hydroxymethylglutarylcoenzyme A reductase and risk of fracture among older women. Lancet. 2000;355:2185-2188.
5. Watanabe S, Fukumoto S, Takeuchi Y, Fujita H, Nakano T, Fujita T. Effects of 1-year treatment with fluvastatin or pravastatin on bone. Am J Med. 2001;110:584-587.
6. Edwards CJ, Hart DJ, Spector TD. Oral statins and increased bone-mineral density in postmenopausal women. Lancet. 2000;355:2218-2219.
7. van Staa T, Wegman S, de Vries F, Leufkens B, Cooper C. Use of statins and risk of fractures. JAMA. 2001;285:1850-1855.
8. LaCroix AZ, Cauley J, Jackson R, et al. Does statin use reduce risk of fracture in postmenopausal women? results from the Womens' Health Initiative Observational Study (WHI-OS). J Bone Miner Res. 2000;15(suppl 1):S155. Abstract 1066.
9. Reid IR, Hague W, Emberson J, et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Lancet. 2001;357:509-512.
10. Pedersen TR, Kjekshus J, 4S Study Group. Statin drugs and the risk of fracture. JAMA. 2000;284:1921-1922.
11. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. N Engl J Med. 1995;332:767-773.
12. Black DM, Cummings SR, Karpf D, FITR Group. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535-1541.
13. Hulley S, Grady D, Bush T, et al, Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
14. Burger H, de Laet C, van Daele P, et al. Risk factors for increased bone loss in an elderly population: the Rotterdam Study. Am J Epidemiol. 1998;147:871-879.
15. Cauley JA, Black DM, Barrett-Connor E, et al. Effects of hormone replacement therapy on clinical fractures and height loss: the Heart and Estrogen/Progestin Replacement Study (HERS). Am J Med. 2001;110:442-450.
16. Black DM, Reiss TF, Nevitt MC, Cauley J, Karpf D, Cummings SR. Design of the Fracture Intervention Trial. Osteoporos Int. 1993;3(suppl 3):S29-S39.
17. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987;9:1-30.
18. National Institutes of Health. Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement. 2000;17(1):1-45.
19. Riggs BL. Overview of osteoporosis. West J Med. 1991;154:63-77.
20. Cummings S, Bauer D. Do statins prevent both cardiovascular disease and fracture? JAMA. 2000;283:3255-3257.
21. Edwards C, Russell R, Spector T. Statins and bone: myth or reality? Calcif Tissue Int. 2001;69:63-66.
22. Demer LL. Boning up (or down) on statins. Arterioscler Thromb Vasc Biol. 2001;21:1565-1566.
23. Sugiyama M, Kodama T, Konishi K, Abe K, Asami S, Oikawa S. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem Biophys Res Commun. 2000;271:688-692.
24. Maeda T, Matsunuma A, Kawane T, Horiuchi N. Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Commun. 2001;280:874-877.
25. Woo J, Kasai S, Stern P, Nagai K. Compactin suppresses bone resorption by inhibiting the fusion of prefusion osteoclasts and disrupting the actin ring in osteoclasts. J Bone Miner Res. 2000;15:650-658.